 The FDA has extended the ongoing review of the marketing application of Ascendis Pharma ASs NASDAQ: ASND TransCon hGH lonapegsomatropin for the treatment of pediatric growth hormone deficiency. Citing a major amendment to the application, the agency has pushed the action goal date by three months to September 25. 